1.
Cancer Treat Rep
; 61(1): 43-5, 1977.
Article
in English
| MEDLINE
| ID: mdl-266418
ABSTRACT
Repeated single doses of busulfan (50-200 mg) were given over 1--2 days to 17 patients with chronic myeloid leukemia. The mean survival time was 137 weeks. In this small trial the drug was shown to be safe in most but not all patients and as effective as continous busulfan.
Subject(s)
Busulfan/therapeutic use , Leukemia, Myeloid/drug therapy , Adult , Aged , Busulfan/administration & dosage , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Evaluation , Follow-Up Studies , Humans , Middle Aged
2.
Aust N Z J Obstet Gynaecol
; 8(1): 20-1, 1968 Feb.
Article
in English
| MEDLINE
| ID: mdl-5239134